Financials

News Discussions Technicals Seasonals

UBM fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to ULISSE BIOMED operating, investing, and financing activities

UBM free cash flow for H1 24 is -1.95 M EUR. For 2023, UBM free cash flow was -1.42 M EUR and operating cash flow was -1.39 M EUR.

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—